Last Updated: June 17, 2026

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Candesartan Cilexetil And Hydrochlorothiazide patents expire, and what generic alternatives are available?

Candesartan Cilexetil And Hydrochlorothiazide is a drug marketed by Apotex Inc, Macleods Pharms Ltd, Pharmobedient, Prinston Inc, Senores Pharms, and Zydus Lifesciences. and is included in six NDAs.

The generic ingredient in CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Candesartan Cilexetil And Hydrochlorothiazide

A generic version of CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE was approved as candesartan cilexetil; hydrochlorothiazide by PHARMOBEDIENT on December 4th, 2012.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
  • What are the global sales for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
  • What is Average Wholesale Price for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
Summary for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
US Patents:0
Applicants:6
NDAs:6

US Patents and Regulatory Information for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 202884-001 Dec 4, 2012 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Lifesciences CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 203466-003 Nov 27, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharmobedient CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 090704-001 Dec 4, 2012 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Macleods Pharms Ltd CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 204100-001 Feb 27, 2015 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Prinston Inc CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 207455-003 Apr 11, 2018 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links